Mailtje van Pharming.

INTERIM UPDATE PHARMING GROUP N.V.

Leiden, December 18, 2003. Pharming Group N.V. (Euronext: PHARM; “Pharming” or “the Company”) announced today that it will be holding a presentation on January 17th 2004 with key medical investigators to announce the results of clinical trials for its lead product, recombinant human C1 inhibitor. Initial results of the clinical trials appear to be positive. Launch of the pivotal study of this product is expected shortly thereafter. The company has increased investment in manufacturing and clinical trials to support a potentially accelerated launch of the C-1 inhibitor.

Outlook
Pharming estimates its loss for the full year 2003 to be in the Euro 10 million range. Furthermore, as stated previously Pharming is in talks with potential strategic partners for the marketing and distribution of the product. The company expects to have finalized such a partnership in the first half of 2004. The company is planning to raise between Euro 5-10 million equity in the first quarter of 2004 through a private placement.

Pharming Group N.V. is developing innovative protein therapeutics for unmet medical needs. The Company’s products include potential treatments for genetic disorders and specialty products for surgical indications. Pharming’s lead product for Hereditary Angioedema is in Phase II of clinical development. The advanced technologies of the Company include novel platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, www.pharming.com

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact:

Europe: USA:
Rein Strijker Samir Singh
Pharming Group N.V. Pharming Group N.V.
T: + 31-(0)71-524-7406 T: + 1-908-720-6224

mvg
Trott